REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (NASDAQ:APPA - News), a specialty pharmaceutical company, has completed patient enrollment in its pivotal Phase 3 study in chemotherapy-induced nausea and vomiting (CINV) comparing the efficacy of APF530 (a proprietary, sustained release formulation of granisetron) with Aloxi for the prevention of acute and delayed onset CINV in both moderate and highly emetogenic chemotherapy treatments. The trial is being conducted in the United States, India and Poland. Data collection will be finalized following completion of treatment of the last patients, expected near the end of July. The results of the trial will be announced following the unblinding of data, which is anticipated to occur late in the third quarter of 2008.
